Thermo Fisher Scientific focuses on digital clinical and spends $8.875 billion in cash to acquire Clario

According to the Zhitong Finance APP, Thermo Fisher Scientific (TMO.US), a leader in life science tools and in vitro diagnostics in the United States, has confirmed that it has reached an acquisition agreement to acquire clinical trial data management company Clario Holdings for $8.875 billion in cash to be paid at closing from a shareholder group led by Astorg, Nordic Capital, Novo Holding, and Cinven. For Thermo Fisher, swallowing Clario will further strengthen its "digital clinical evidence" business capabilities. This transaction has immediate financial appeal in terms of enhancing profit margins and adjusted EPS, and bets on the long-term trend of FDA-guided DHT/DCT (Digital Health Technologies/Decentralized Trials). This major acquisition is expected to be completed by mid-2026, subject to customary closing conditions and formal approval from U.S. regulators. After the acquisition is completed, Clario will be integrated into Thermo Fisher's laboratory products and biopharmaceutical services business unit. According to a recent acquisition statement, in addition to the initial cash purchase price at closing, Thermo Fisher has agreed to pay $125 million in January 2027 and up to $400 million in contingent consideration based on the business's specific performance in 2026 and 2027. Public information shows that Clario integrates clinical trial endpoint data from endpoint detection/diagnostic devices, trial centers, and patients, enabling large clients in the pharmaceutical and biotechnology sectors to digitally collect, manage, and analyze clinical trial evidence at every stage of drug development. Over the past decade, the company's platform has supported approximately 70% of FDA drug approval processes. For the full year of 2025, this business is expected to generate approximately $1.25 billion in revenue. Under Thermo Fisher's ownership, this business is expected to achieve high unit-level growth. Marc N. Casper, Chairman, President, and CEO of Thermo Fisher, stated: "Clario is strategically aligned with us, enabling faster and more insightful drug development processes through differentiated technology and data intelligence solutions." This acquisition is expected to have a positive accretive effect on Thermo Fisher's adjusted operating profit margin in the first year after closing and to increase adjusted earnings per share by $0.45 in the first year after closing. The company expects to achieve approximately $175 million in adjusted operating profit after synergies in the fifth year following the completion of the acquisition. Analysts have stated that Thermo Fisher's acquisition of Clario further strengthens its "digital clinical evidence" capabilities after its acquisition of PPD (CRO): integrating eCOA, medical imaging, ECG/breathing, safety monitoring, wearable and site data into its own system, thereby connecting and digitizing the evidence chain from drug development to clinical trials to registration to commercialization, thus achieving higher customer stickiness, cross-selling, and sustainable growth, aiming to fully embed a "regulatory-grade clinical endpoint data platform" into its vast biopharmaceutical customer ecosystem Under the clear push from the FDA for DHT/DCT, eCOA/imaging/wearables to become the "new normal" in clinical settings, this acquisition by Thermo Fisher Scientific can be said to embody threefold value: cutting-edge strategic positioning, financial enhancement, and synergy within the medical ecosystem